Protara 3Q financials and updates TARA-002 manufacturing
Protara reported $143M cash and highlighted milestone progress for its TARA-002 treatments in NMIBC and lymphatic malformations, including the in-house acquisition of manufacturing assets.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed